Veru (VERU)
(Delayed Data from NSDQ)
$0.95 USD
0.00 (0.18%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $0.95 0.00 (0.21%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VERU 0.95 0.00(0.18%)
Will VERU be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VERU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VERU
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
VERU: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Veru (VERU) a New Buy Stock
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?
Other News for VERU
Warning: VERU is at high risk of performing badly
Buy Rating Affirmed for Veru’s Enobosarm on Positive Trial Results and Market Opportunity
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
VERU Stock Earnings: Veru Beats EPS, Misses Revenue for Q1 2024
Veru management to meet virtually with B. Riley